Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MEDNAX, INC.

(MD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

MEDNAX, Inc. : After the gains, a correction ?

07/30/2020 | 09:52am EDT
short sell
Stop-loss triggered
Entry price : 19.58$ | Target : 15.1$ | Stop-loss : 21.5$ | Potential : 22.88%
MEDNAX, Inc. shares could experience selling pressure following the strong increase in its stock price. Over the short term, the stock in fact displays first signs of exhaustion.
Investors should open a short trade and target the $ 15.1.
MEDNAX, Inc. : MEDNAX, Inc. : After the gains, a correction ?
Summary
  • The company usually posts poor financials for mid or long term investments.

Weaknesses
  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • Low profitability weakens the company.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 45.77 times its estimated earnings per share for the ongoing year.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.

ę MarketScreener.com 2020

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2021 1 826 M - -
Net income 2021 81,0 M - -
Net Debt 2021 232 M - -
P/E ratio 2021 32,1x
Yield 2021 -
Capitalization 2 713 M 2 713 M -
EV / Sales 2021 1,61x
EV / Sales 2022 1,73x
Nbr of Employees 5 600
Free-Float 97,3%
Upcoming event on MEDNAX, INC.
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 28,63 $
Last Close Price 31,89 $
Spread / Highest target 9,75%
Spread / Average Target -10,2%
Spread / Lowest Target -34,1%
EPS Revisions
Managers and Directors
NameTitle
Mark S. Ordan Chief Executive Officer & Director
Roger Mack Hinson President
C. Mark Richards Chief Financial Officer & Executive Vice President
Guy P. Sansone Chairman
Mary Ann E. Moore Chief Legal Officer, SVP & Head-Operations
Sector and Competitors
1st jan.Capitalization (M$)
MEDNAX, INC.29.95%2 713
CVS HEALTH CORPORATION25.04%111 408
HCA HEALTHCARE, INC.27.42%68 730
REDE D'OR SÃO LUIZ S.A.-0.10%26 648
LABORATORY CORPORATION OF AMERICA HOLDINGS27.94%25 370
FRESENIUS MEDICAL CARE AG & CO. KGAA1.70%24 498